Latest Quinazolines Stories
A treatment that combines a chemotherapy agent that is approved to treat breast cancer and a cancer-fighting antibody may be a promising therapy for colon cancer, according to new research.
CHICAGO and SAN DIEGO, June 6, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc.
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies.
WALTHAM, Mass., June 2, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No.
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies in the early 2000s.
OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc.
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
A subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments and may not need chemotherapy.
BROOMFIELD, Colo., April 28, 2011 /PRNewswire/ -- Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy").
Two sets of gene expression profiles predict response to a common lung cancer drug for patients that have no guiding indicators for their treatment now.